# Pqq Fatigue Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/pqq-fatigue-randomized-trial-evidence-review
Category: evidence-review
Summary: Pqq Fatigue Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized
Last reviewed: 2026-06-24
Reviewed by: Migaku Evidence Review
# Pqq Fatigue Randomized Trial: What the Evidence Says

## Quick Answer

Pqq Fatigue Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| The effects of pyrroloquinoline quinone and nicotinamide mononucleotide supplementation on interoception following acute exhaustive exercise: a randomised, double-blind, placebo-controlled study | randomized trial | 2 | 2026-02-06 | 10.1038/s41598-025-34191-0 |
| A role for the antioxidants coenzyme Q10 and pyrroloquinoline quinone in mitigating obesity-associated reproductive dysfunction † | research article | 4 | 2026-01-01 | 10.1093/biolre/ioaf185 |

## What The Sources Report

- During exercise, various internal changes such as increased heart and respiratory rates, muscle pain, and emotional fluctuations are transmitted to the central nervous system. [Zhao Chenxi (2026); evidence level 2]
- This process, referred to as "exercise interoception", is enhanced by exercise via stimulated visceral signals, increased peripheral sensitivity, and improved neural plasticity. [Zhao Chenxi (2026); evidence level 2]
- While obesity is known to be associated with health risks such as hypertension and diabetes in the general population, it confers additional risks to both mother and fetus during pregnancy. [Castillo-Castrejon Marisol (2026); evidence level 4]
- Risks of obesity in early pregnancy include increased risk of miscarriage as well as fetal anomalies, including neural tube defects, cardiac anomalies, oral facial clefts, and limb reduction anomalies. [Castillo-Castrejon Marisol (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For pqq fatigue randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Zhao Chenxi (2026). The effects of pyrroloquinoline quinone and nicotinamide mononucleotide supplementation on interoception following acute exhaustive exercise: a randomised, double-blind, placebo-controlled study. DOI: 10.1038/s41598-025-34191-0. PMCID: PMC12886864. PMID: 41651893. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12886864/
- Castillo-Castrejon Marisol (2026). A role for the antioxidants coenzyme Q10 and pyrroloquinoline quinone in mitigating obesity-associated reproductive dysfunction †. DOI: 10.1093/biolre/ioaf185. PMCID: PMC12808547. PMID: 40810470. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Acces.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12808547/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.